Loading
CRISPR and Genetic Engineering · Journal article
International Journal of Basic & Clinical Pharmacology · August 24, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of CRISPR-Cas9 technology that summarizes the discovery, mechanism, and theoretical therapeutic potential across multiple genetic disorders, but does not present clinical trial data, patient outcomes, or evidence synthesis. It identifies technical and immunological barriers to clinical translation without quantifying their impact or reporting solutions that have been validated in humans.
Journal article.
CRISPR-Cas9 uses RNA-guided nucleases to precisely alter DNA sequences and is applicable to hemoglobinopathies, sickle cell disease, β-thalassemia, hereditary retinal diseases, muscular dystrophies, liver metabolic disorders, congenital lung diseases, and genetic deafness Off-target effects, PAM sequence restrictions, DNA damage-induced toxicity, and immunological responses to Cas proteins limit clinical applicability Improvements in delivery methods and high-fidelity Cas9 variants are being developed to address current limitations
No specific evidence on the prevalence or magnitude of off-target effects, toxicity, or immunological responses Off-target effects, PAM sequence restrictions, DNA damage-induced toxicity, and immunological responses to Cas proteins limit clinical applicability
The source did not state who this applies to in practice.
This is a narrative review article that surveys CRISPR technology, mechanisms, and potential applications without reporting original empirical data, clinical outcomes, or evidence synthesis from trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The adaptive immune system of prokaryotes is the source of CRISPR-Cas9, a ground-breaking genome editing technique that uses RNA-guided nucleases to precisely alter DNA sequences. An summary of CRISPR/Cas9's discovery, structural elements, mode of action, therapeutic uses, and present limitations is given in this article. The Cas9 nuclease and guide RNA work together to identify particular DNA targets and cause double-strand breaks in the system. Cellular processes like homology-directed repair or non-homologous end joining fix these defects, allowing for gene disruption or correction. Numerous genetic abnormalities, such as hemoglobinopathies including sickle cell disease and β-thalassemia, hereditary retinal diseases, muscular dystrophies, liver metabolic disorders, congenital lung diseases, and genetic deafness, have showed great potential for treatment with CRISPR/Cas9. Clinical applicability is limited by issues such off-target effects, PAM sequence restrictions, DNA damage-induced toxicity, and immunological responses to Cas proteins, despite its wide therapeutic potential. These obstacles are being addressed by improvements in delivery methods and high-fidelity Cas9 variations. All things considered, CRISPR/Cas9 is a revolutionary development in molecular medicine and gene therapy, providing strong prospects for accurate genome engineering and upcoming clinical uses in personalized medicine.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.